Novo Nordisk will rebuild a facility in Treyburn, North Carolina acquired from Purdue Pharma to support an oral form of its GLP-1 analogue semaglutide. In an email sent to staff and posted on cafepharma.com, Craig Landau – CEO of OxyContin maker Purdue Pharma – said an evaluation of his firm’s manufacturing operations and capabilities has resulted in the sale of its Treyburn solid oral dose plant to Danish drugmaker Novo Nordisk. Financial details of the deal have not been divulged,…
Biocon says it is making a “very significant expansion†in its manufacturing capacity to feed the demand for biosimilars, including its pegfilgrastim product Fulphila. In June 2018, Fulphila became the first biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim) to win US Food and Drug Administration (FDA) approval. The biosimilar is marketed in the region by Mylan but manufactured by partner Biocon. In its Q1 FY2020 results, the Indian drugmaker claimed Fulphila captured a 21% volume share of the US pegfilgrastim…